C-MHT7Longevity Biotech
immune rebalancing, Hybridtides, precision neuroscience
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-MHT7
C-MHT7C-MHT7immune rebalancing, Hybridtides, precision neuroscience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Longevity Biotech immune rebalancing, Hybridtides, precision neuroscience
Longevity Biotech is focused on changing the neuroscience paradigm for neurodegenerative diseases by developing products that reset dysregulated immune systems. Its initial focus is Parkinson's Disease, with expansion into related neurodegenerative diseases. The company uses a Precision Neuroscience Platform to profile immune biomarkers and a proprietary Hybridtide Platform for synthetic peptide-based therapeutics.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Longevity Biotech — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic